NIST Consortium for Advancement of Genome Editing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The National Institute of Standards and Technology (NIST) extends the duration of the NIST Consortium for Advancement of Genome Editing (Genome Editing Consortium or Consortium). The Consortium duration was previously through December 1, 2025. NIST is taking this action to provide additional time for interested parties to join the Consortium to further pursue the implementation and achievement of outcomes of the current Consortium activities, as well as to address additional standards needs as defined by the Consortium in qualification of off-target assays and quality of genome editing components. Beginning January 1, 2026 participation fees will increase to $25,000 annually or in-kind contributions of equivalent value. Participants will be required to sign a Cooperative Research and Development Agreement (CRADA).
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 205 (Wednesday, October 23, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 205 (Wednesday, October 23, 2024)]
[Notices]
[Page 84534]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-24514]
[[Page 84534]]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
National Institute of Standards and Technology
NIST Consortium for Advancement of Genome Editing
AGENCY: National Institute of Standards and Technology, Department of
Commerce.
ACTION: Notice of Research Consortium; Extension of Research
Consortium.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Standards and Technology (NIST)
extends the duration of the NIST Consortium for Advancement of Genome
Editing (Genome Editing Consortium or Consortium). The Consortium
duration was previously through December 1, 2025. NIST is taking this
action to provide additional time for interested parties to join the
Consortium to further pursue the implementation and achievement of
outcomes of the current Consortium activities, as well as to address
additional standards needs as defined by the Consortium in
qualification of off-target assays and quality of genome editing
components. Beginning January 1, 2026 participation fees will increase
to $25,000 annually or in-kind contributions of equivalent value.
Participants will be required to sign a Cooperative Research and
Development Agreement (CRADA).
DATES: The Consortium's activities will continue as needed to complete
the updated research plan. NIST will accept letters of interest to
participate in this Consortium on an ongoing basis. Acceptance of
participants into the Consortium will depend on the availability of
resources.
ADDRESSES: Information in response to this notice, including completed
letters of interest or requests for additional information about the
Consortium, can be directed via mail to the Consortium Manager, Dr.
Samantha Maragh, Biosystems and Biomaterials Division of NIST's
Material Measurement Laboratory, 100 Bureau Drive, Mail Stop 8312,
Gaithersburg, Maryland 20899 or via electronic mail to
<a href="/cdn-cgi/l/email-protection#0271636f636c766a63426c6b71762c656d74"><span class="__cf_email__" data-cfemail="74071519151a001c15341a1d07005a131b02">[email protected]</span></a>, or by telephone at (301) 975-4947.
SUPPLEMENTARY INFORMATION: On January 11, 2018, NIST published a notice
in the Federal Register (83 FR 1335), establishing the Consortium, and
on February 2, 2021, NIST published a notice in the Federal Register
(86 FR 7859) extending the duration of the Consortium until December 1,
2025. To provide additional time for interested parties to join the
Consortium to further pursue the implementation and achievement of the
Consortium objectives, NIST extends the term to continue as needed to
complete the updated research plan and will accept letters of interest
on an ongoing basis. Previously submitted letters of interest do not
need to be resubmitted.
The Consortium's current activities (as described in the original
notice, 83 FR 1335) will continue, and the Consortium research plan is
amended to include the following new activities:
Qualification of Off-Target Assays: Identify sources of variability
and develop consensus approaches to qualifying off-target assays
(including potential interlaboratory studies or control materials).
Quality of Genome Editing Components: Identify concepts/
information, approaches/assays, and potential controls for assessing
quality of genome editing components.
Alicia Chambers,
NIST Executive Secretariat.
[FR Doc. 2024-24514 Filed 10-22-24; 8:45 am]
BILLING CODE 3510-13-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.